New Zealand markets closed

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.49+0.13 (+2.43%)
At close: 04:00PM EST
5.61 +0.12 (+2.19%)
After hours: 08:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 221.47M
Enterprise value 118.50M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)25.84
Price/book (mrq)2.59
Enterprise value/revenue 16.45
Enterprise value/EBITDA -2.44

Trading information

Stock price history

Beta (5Y monthly) 2.59
52-week change 3153.00%
S&P500 52-week change 327.79%
52-week high 35.60
52-week low 31.01
50-day moving average 33.16
200-day moving average 32.28

Share statistics

Avg vol (3-month) 3298.59k
Avg vol (10-day) 3603.79k
Shares outstanding 540.71M
Implied shares outstanding 640.71M
Float 89.2M
% held by insiders 10.90%
% held by institutions 187.08%
Shares short (31 Jan 2024) 442.91k
Short ratio (31 Jan 2024) 40.19
Short % of float (31 Jan 2024) 40.13%
Short % of shares outstanding (31 Jan 2024) 40.11%
Shares short (prior month 29 Dec 2023) 476.95k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023


Profit margin 0.00%
Operating margin (ttm)-444.45%

Management effectiveness

Return on assets (ttm)-31.77%
Return on equity (ttm)-59.95%

Income statement

Revenue (ttm)7.2M
Revenue per share (ttm)0.21
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -52.86M
Net income avi to common (ttm)-49.11M
Diluted EPS (ttm)-1.48
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)108.03M
Total cash per share (mrq)2.65
Total debt (mrq)5.06M
Total debt/equity (mrq)5.93%
Current ratio (mrq)4.59
Book value per share (mrq)2.10

Cash flow statement

Operating cash flow (ttm)-33.8M
Levered free cash flow (ttm)-17.52M